DUBLIN, Ireland, March 9 /PRNewswire/ -- Biotrin today announced an agreement with BD Biosciences, a segment of BD (Becton, Dickinson and Company), for the distribution of Biotrin’s biomarker range of products for the detection of early organ damage. Under the terms of the distribution agreement, BD Biosciences has been appointed as world-wide distributor of the Biotrin Biomarkers product range to pharmaceutical companies, contract research organisations, universities and research centres.
“We believe this agreement will enable us to capitalize on the growing demand for our expanding biomarker product line and help achieve our goal of making Biotrin Biomarkers the number one choice for the detection of early organ damage,” said Dr. Cormac G. Kilty, CEO of Biotrin. “With the sales and marketing teams from Biotrin and BD Biosciences working together, we will expand the reach of this product line throughout the world.”
Biotrin identifies and selects biomarkers of interest using proprietary HISTOMICS(R) technology. Biotrin Biomarkers provide specific and quantitative information allowing researchers to determine the exact location and amount of damage an organ has undergone and to monitor the progression of damage, either as a result of disease or the administration of toxic compounds. Biotrin Biomarkers have been on the market for several years, and the number of products in the range continues to grow.
Under the agreement, BD Biosciences will sell the Biotrin Biomarkers product range throughout the world. Other terms of the agreement were not disclosed.
About Biotrin International
Biotrin International develops, manufactures and markets in vitro devices for niche viruses and novel markers of organ damage, using proprietary materials and methods. These products are sold internationally to various public and private laboratories, clinics, hospitals and research centres, and other leading commercial, industrial and government entities.
Biotrin is the leading supplier of biomarker assays for the detection of early organ damage as a result of disease and/or toxic compounds. For more information on the Company, please go to www.biotrin.com
Biotrin International Ltd.
CONTACT: Biotrin International, Vicky McGrath - Ph. +353-(0)1-283-1166
